Literature DB >> 16758362

Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine.

Michael P Smith1, Anita Fletcher-Turner, David M Yurek, Wayne A Cass.   

Abstract

Calcitriol has been implicated as an agent that has neuroprotective effects in various animal models of diseases, possibly by upregulating glial cell line-derived neurotrophic factor (GDNF). The present study examined the neuroprotective effects of calcitriol in a model of early Parkinson's disease. Rats were treated daily with calcitriol or saline for 7 days before an intraventricular injection of 6-hydroxydopamine (6-OHDA), and then for 1 day or daily for 3(1/2) to 4 weeks after lesioning. Evoked overflow and tissue content of dopamine (DA) were determined 3(1/2) to 4 weeks post lesion. The 8-day calcitriol treatment did not attenuate 6-OHDA-induced decreases in evoked overflow of DA, nor did it protect against 6-OHDA-induced reductions in tissue levels of DA in the striatum or substantia nigra. However, the long-term calcitriol treatment did significantly increase evoked overflow of DA, as well as the amount of DA in the striatum, compared to saline treated animals. GDNF was significantly increased in the substantia nigra, but not in the striatum, of non-lesioned, calcitriol treated rats. These results suggest that long-term treatment with calcitriol can provide partial protection for dopaminergic neurons against the effects of intraventricularly administered 6-OHDA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16758362     DOI: 10.1007/s11064-006-9048-4

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  44 in total

1.  Zinc-induced apoptosis in substantia nigra of rat brain: neuroprotection by vitamin D3.

Authors:  Anya M Y Lin; S F Fan; D M Yang; L L Hsu; C H J Yang
Journal:  Free Radic Biol Med       Date:  2003-06-01       Impact factor: 7.376

2.  Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease.

Authors:  Y Sato; S Manabe; H Kuno; K Oizumi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

3.  Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine.

Authors:  B Moghaddam; B S Bunney
Journal:  J Neurochem       Date:  1989-08       Impact factor: 5.372

4.  Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.

Authors:  C Rosenblad; D Kirik; A Björklund
Journal:  Exp Neurol       Date:  2000-02       Impact factor: 5.330

5.  Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3.

Authors:  E Garcion; L Sindji; C Montero-Menei; C Andre; P Brachet; F Darcy
Journal:  Glia       Date:  1998-03       Impact factor: 7.452

6.  1,25-Dihydroxyvitamin D3 regulates gamma 1 transpeptidase activity in rat brain.

Authors:  E Garcion; X D Thanh; F Bled; E Teissier; M P Dehouck; F Rigault; P Brachet; A Girault; G Torpier; F Darcy
Journal:  Neurosci Lett       Date:  1996-10-04       Impact factor: 3.046

7.  HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat.

Authors:  Wayne A Cass; Michael E Harned; Laura E Peters; Avindra Nath; William F Maragos
Journal:  Brain Res       Date:  2003-09-12       Impact factor: 3.252

8.  Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra.

Authors:  Michael F Salvatore; Jin-Lu Zhang; Delia M Large; Patsy E Wilson; Clelland R Gash; Theresa Currier Thomas; John W Haycock; Guoying Bing; John A Stanford; Don M Gash; Greg A Gerhardt
Journal:  J Neurochem       Date:  2004-07       Impact factor: 5.372

9.  Rate of cell death in parkinsonism indicates active neuropathological process.

Authors:  P L McGeer; S Itagaki; H Akiyama; E G McGeer
Journal:  Ann Neurol       Date:  1988-10       Impact factor: 10.422

10.  GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.

Authors:  C M Kearns; D M Gash
Journal:  Brain Res       Date:  1995-02-20       Impact factor: 3.252

View more
  39 in total

1.  Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats.

Authors:  Wayne A Cass; Laura E Peters; Anita M Fletcher; David M Yurek
Journal:  Neurochem Int       Date:  2011-11-22       Impact factor: 3.921

2.  Calcitriol promotes augmented dopamine release in the lesioned striatum of 6-hydroxydopamine treated rats.

Authors:  Wayne A Cass; Laura E Peters; Anita M Fletcher; David M Yurek
Journal:  Neurochem Res       Date:  2014-05-25       Impact factor: 3.996

Review 3.  Vitamin D and the occurrence of depression: causal association or circumstantial evidence?

Authors:  Elizabeth R Bertone-Johnson
Journal:  Nutr Rev       Date:  2009-08       Impact factor: 7.110

4.  Vitamin D receptor gene polymorphisms and Parkinson's disease in a population with high ultraviolet radiation exposure.

Authors:  Nicole M Gatto; Janet S Sinsheimer; Myles Cockburn; Loraine A Escobedo; Yvette Bordelon; Beate Ritz
Journal:  J Neurol Sci       Date:  2015-04-07       Impact factor: 3.181

5.  Associations between vitamin D levels and depressive symptoms in healthy young adult women.

Authors:  David C R Kerr; David T Zava; Walter T Piper; Sarina R Saturn; Balz Frei; Adrian F Gombart
Journal:  Psychiatry Res       Date:  2015-03-05       Impact factor: 3.222

Review 6.  Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system.

Authors:  Mercedes Garcia-Gil; Federica Pierucci; Ambra Vestri; Elisabetta Meacci
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

7.  Vitamin D receptor gene as a candidate gene for Parkinson disease.

Authors:  Megan W Butler; Amber Burt; Todd L Edwards; Stephan Zuchner; William K Scott; Eden R Martin; Jeffery M Vance; Liyong Wang
Journal:  Ann Hum Genet       Date:  2011-03       Impact factor: 1.670

8.  The transcriptomic response of mixed neuron-glial cell cultures to 1,25-dihydroxyvitamin d3 includes genes limiting the progression of neurodegenerative diseases.

Authors:  Marie-France Nissou; Jacques Brocard; Michèle El Atifi; Audrey Guttin; Annie Andrieux; François Berger; Jean-Paul Issartel; Didier Wion
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

9.  Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk.

Authors:  Srishti Shrestha; Pamela L Lutsey; Alvaro Alonso; Xuemei Huang; Thomas H Mosley; Honglei Chen
Journal:  Mov Disord       Date:  2016-04-19       Impact factor: 10.338

10.  Evidence for the Importance of Vitamin D Status in Neurologic Conditions.

Authors:  Anusha K Yeshokumar; Deanna Saylor; Michael D Kornberg; Ellen M Mowry
Journal:  Curr Treat Options Neurol       Date:  2015-12       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.